With 12,680,593 votes – representing 99.57% of the share capital present – the merger was approved, marking an impressive vote of confidence in VERAXA’s strategic development. The transaction will be executed as an absorption merger, under which Veraxa Biotech Holding AG, as the acquiring entity, will integrate VERAXA Biotech AG and subsequently be renamed Veraxa Biotech AG. The existing management team, led by CEO Dr. Christoph Antz, will continue to steer the company’s operations.

Dr. Christoph Antz, CEO of VERAXA Biotech AG, commented: «We are grateful for the strong support of our shareholders. VERAXA is exceptionally well positioned to create long-term value and advance patient-focused, innovative cancer therapies.»

Oliver R. Baumann, CEO of Xlife Sciences AG, added: «The clear approval from shareholders underscores the confidence in VERAXA’s strategic direction and validates our approach of guiding scientifically outstanding platforms toward the capital markets. VERAXA combines strong technology, excellent science, and an experienced management team – the ideal foundation for sustainable success on the international stage.»

Further details on the Extraordinary General Meeting are available on the VERAXA Biotech AG website (link). Following approval by Voyager’s shareholders on 12 March 2026, the merger will be completed and trading will commence shortly thereafter. The information published in this context represents a summary only. Full details can be found in the transaction documents filed with the U.S. Securities and Exchange Commission (SEC) and in Voyager’s proxy statement/prospectus dated 19 February 2026.

Financial calendar